

### **AMENDMENTS TO THE SPECIFICATION**

Please add the following new paragraph after the title on page 1 line 3:

#### **-- Cross-Reference to Related Applications**

The present patent application is a §371 of International Application No. PCT/CN2004/001064 filed on September 20, 2004 and claiming priority to Chinese patent application serial no. 03146951.5 filed on September 26, 2003 in the names of Guoqiao Li, et al.

--

#### **Background art**

In the specification at page 1 line 8, please replace the paragraph starting with "Among the prior art" with the following amended paragraph:

-- Among the prior art anti-malaria drugs, some employ artemisinin derivatives (such as dihydroartemisinin, artesunate, artemether, arteether) in conjunction with piperazine having a long half-life. GI tract side effects such as nausea and vomiting due to substantial amount of phosphates adversely affect the therapeutic effects, with incidence of up to 10% when the total amount for one course is divided into 3 doses, and reduced to 3-5% when divided into 4 doses. In addition, the prior art anti-malaria drugs suffer from the disadvantages of long processing period, high production cost, short shelf life, large dosage and the like. --

#### **Disclosure of the Invention**

In the specification at page 1 lines 29-30, please replace with the following lines 29 and 30:

-- piperazine, 5 parts  
primaquine, 0-0.05 part, --

**Embodiment of the Invention**

In the specification at page 2 line 1, please replace with the following line 1:

-- the optimum ratio being 1:5:0.04. --

In the specification at page 2 after line 12, please replace the table with the following amended table:

Artemisinin	160 g
Piperaquine	750 g
Primaquine	6 g
Adjuvant (hydroxypropyl cellulose and etc.)	q.s.
to produce	1,000 Tablets